Is Genmab (CPSE:GMAB) Pricing Reflect Its Recent Biotech Momentum And DCF Upside Potential [Yahoo! Finance]
Genmab A/S - American Depositary Shares (GMAB)
Company Research
Source: Yahoo! Finance
If you are wondering whether Genmab shares offer good value today, you are not alone. That is exactly what this article is going to unpack for you. The stock recently closed at DKK 2,164, with returns of 0.7% over 7 days, 8.9% over 30 days, 7.8% year to date, 41.9% over 1 year, and longer term 20.1% and 18.0% declines over 3 and 5 years. Recent news coverage around Genmab has focused on its role as a key Danish pharmaceuticals and biotech name. This helps explain why shorter term returns differ from the weaker multi year picture. This context matters because sentiment around its pipeline, partnerships and sector positioning often feeds directly into how investors think about what the stock is worth. Genmab currently scores 5 out of 6 on our valuation checks. This sets up a closer look at how different methods value the company and, later in the article, a more complete way to judge whether that valuation really makes sense. Genmab delivered 41.9% returns over the last year. S
Show less
Read more
Impact Snapshot
Event Time:
GMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GMAB alerts
High impacting Genmab A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
GMAB
News
- Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Yahoo! Finance]Yahoo! Finance
- Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)Business Wire
- Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)GlobeNewswire
- Genmab A/S (GMAB): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Anthropic unveils Claude for Healthcare, expands life science features, and partners with HealthEx to let users connect medical records [Fortune]Fortune